^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    abiraterone acetate

    i
    Other names: CB 7630, JNJ-212082, CB-7630, CB7630, BR9004
    Company:
    Generic mfg.
    Drug class:
    CYP17A1 inhibitor
    Related drugs:
    3d
    A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer (clinicaltrials.gov)
    P2, N=218, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    abiraterone acetate • zeprumetostat (SHR-2554) • AiRuiEn (rezvilutamide) • risvutatug rezetecan (GSK5764227)
    7d
    CHOMP: A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, VA Office of Research and Development | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Dec 2026
    Enrollment closed • Trial completion date • Checkpoint inhibition • Mismatch repair
    |
    EGFR (Epidermal growth factor receptor) • MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • CDK12 (Cyclin dependent kinase 12) • PMS1 (PMS1 protein homolog 1)
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • abiraterone acetate
    7d
    Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer (clinicaltrials.gov)
    P2, N=26, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial primary completion date: Dec 2025 --> Oct 2026
    Trial primary completion date
    |
    Xtandi (enzalutamide) • abiraterone acetate • apalutamide • Provenge (sipuleucel-T)
    8d
    PARP Inhibitors Combined with Abiraterone Overcome Resistance in Metastatic Castration-Resistant Prostate Cancer Independently of Androgen Receptor. (PubMed, Cancers (Basel))
    Overall, the results indicate that maintaining Abiraterone treatment in combination with PARPis after resistance develops provides superior therapeutic efficacy compared to PARP inhibition alone, offering a promising strategy for managing Abiraterone-resistant prostate cancer. Combining Abiraterone with PARPis enhances therapeutic efficacy and overcomes the acquired insensitivity in mCRPC with BRCA1/2 or HRR mutations. These results support continued use of PARPis with Abiraterone to improve clinical outcomes.
    Journal • BRCA Biomarker • PARP Biomarker • IO biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • AR (Androgen receptor) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA wild-type
    |
    Lynparza (olaparib) • Zejula (niraparib) • abiraterone acetate
    9d
    CDZR123A12107: A clinical trial to learn about the effects of DZR123 and JSB462 given together in men with advanced prostate cancer that has stopped responding to other treatments (2025-521880-10-00)
    P1/2, N=76, Recruiting, Novartis Pharma AG | Not yet recruiting --> Recruiting
    Enrollment open
    |
    docetaxel • Xtandi (enzalutamide) • abiraterone acetate • cabazitaxel • tulmimetostat (DZR123) • luxdegalutamide (ARV-766)
    10d
    APEX-01: ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer (clinicaltrials.gov)
    P1, N=183, Active, not recruiting, Janssen Research & Development, LLC | N=50 --> 183
    Enrollment change • First-in-human
    |
    FOLH1 positive
    |
    abiraterone acetate • prednisone • apalutamide • JNJ-8177
    16d
    A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder (clinicaltrials.gov)
    P2, N=12, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=60 --> 12
    Enrollment closed • Enrollment change
    |
    cisplatin • Imfinzi (durvalumab) • doxorubicin hydrochloride • abiraterone acetate • vinblastine
    17d
    Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) (clinicaltrials.gov)
    P1/2, N=1200, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Oct 2027 --> Jul 2028
    Trial completion date
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib) • carboplatin • docetaxel • Lenvima (lenvatinib) • Xtandi (enzalutamide) • abiraterone acetate • etoposide IV • prednisone • dexamethasone • Welireg (belzutifan) • vibostolimab/pembrolizumab (MK-7684A)
    17d
    APEX-01: ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer (clinicaltrials.gov)
    P1, N=50, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting | N=183 --> 50 | Trial completion date: Dec 2028 --> Dec 2026 | Trial primary completion date: Jun 2027 --> Dec 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    FOLH1 positive
    |
    abiraterone acetate • prednisone • apalutamide • JNJ-8177
    17d
    20230239: Phase 3 Study of Xaluritamig Plus Abiraterone vs Investigator's Choice in Chemotherapy-nave Metastatic Castration-resistant Prostate Cancer (2025-520555-89-00)
    P2/3, N=295, Recruiting, Amgen Inc.
    New P2/3 trial
    |
    docetaxel • abiraterone acetate • cabazitaxel • Sylvant (siltuximab) • xaluritamig (AMG 509)
    17d
    5541-CL-0201: A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants with Prostate Cancer (2024-517653-27-00)
    P1/2, N=89, Recruiting, Astellas Pharma Global Development Inc.
    New P1/2 trial
    |
    abiraterone acetate • prednisone • abiraterone decanoate (ASP5541)
    17d
    D9727C00001: A study to evaluate the impact on metastases-free survival with the addition of saruparib vs placebo to a standard radiotherapy androgen deprivation regimen in men with high-risk prostate cancer with a BRCA mutation. (2024-513586-39-00)
    P2/3, N=253, Recruiting, AstraZeneca AB
    New P2/3 trial
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    abiraterone acetate • saruparib (AZD5305)